An is a medical device designed to deliver medication directly into the lungs and airways, primarily for the management of chronic respiratory conditions such as and . By administering drugs in the form of an aerosol, dry powder, or vapor, inhalers enable targeted treatment that maximizes therapeutic effects while minimizing systemic side effects. Commonly used medications include like for rapid relief of bronchospasm, and such as to reduce airway inflammation over time. Various types of inhalers exist, including , , and , each differing in mechanism, ease of use, and patient suitability. Proper technique is crucial, as incorrect use significantly reduces drug delivery to the lungs; tools like or can improve efficacy, especially in children or those with coordination difficulties. The choice of device depends on factors such as patient age, inspiratory flow rate, and cognitive ability, with guidance from healthcare professionals including and . Advances in inhaler technology now include smart inhalers with integrated and digital tracking to enhance adherence, while environmental concerns have led to the development of propellant-free or low-global-warming-potential alternatives. Regulatory standards such as and ensure device performance and biocompatibility, and public health initiatives promote equitable access to inhalation therapies worldwide [1].
Types of Inhalers and Their Mechanisms
Inhalers are medical devices designed to deliver medication directly into the lungs and airways, with distinct types differing in their mechanisms of action, patient requirements, and clinical applications. The primary categories include , , and , each utilizing unique technological principles to aerosolize or disperse medication for inhalation [2].
Pressurized Metered-Dose Inhalers (pMDI)
Pressurized metered-dose inhalers (pMDIs), also known as aerosol inhalers, deliver a precise dose of medication in the form of a fine spray through the use of a pressurized propellant. These devices consist of a canister containing the medication suspended or dissolved in a gas propellant, typically hydrofluoroalkanes (HFA) such as HFA-134a, which have replaced ozone-depleting chlorofluorocarbons (CFCs) in compliance with the [3]. Activation occurs when the patient depresses the canister, releasing a measured dose of medication as an aerosol.
A critical factor in the effectiveness of pMDIs is the coordination between actuation and inhalation. The patient must begin a slow, deep inhalation at the exact moment the device is activated to ensure optimal deposition of the medication in the lower airways [4]. Poor coordination often results in oropharyngeal deposition, reducing pulmonary delivery and increasing the risk of local side effects such as oral .
To overcome this challenge, the use of a or holding chamber is highly recommended, particularly for children, elderly patients, or those with difficulty coordinating their breathing. Spacers act as artificial dead space, allowing the medication to be released into a chamber before inhalation, thus decoupling actuation from inspiration. This significantly improves lung deposition, reduces oropharyngeal side effects, and enhances overall therapeutic efficacy [5]. Modern pMDIs may also include dose counters to help patients track remaining doses and prevent unintentional use of empty devices [6].
Dry Powder Inhalers (DPI)
Dry powder inhalers (DPIs) deliver medication in the form of a micronized powder that is activated by the patient’s own inspiratory effort. Unlike pMDIs, DPIs do not require a propellant or hand-breath coordination, making them more user-friendly for patients who can generate sufficient inspiratory flow [7]. Common examples include the , , , and , each with unique internal mechanisms for powder dispersion.
The effectiveness of DPIs is highly dependent on the patient’s ability to inhale rapidly and forcefully, typically requiring an inspiratory flow rate exceeding 60 L/min to adequately deaggregate the powder and generate an inhalable aerosol [8]. This makes them less suitable for individuals with severe respiratory impairment, such as those experiencing acute exacerbations of or very young children with limited lung capacity.
DPIs offer several advantages, including portability, ease of use, and a more favorable environmental profile due to the absence of greenhouse gas propellants. They are often preferred for long-term maintenance therapy in stable patients with adequate inspiratory strength [9]. However, their performance can be compromised by exposure to humidity, which may cause powder clumping and reduced dose emission, necessitating careful storage in dry environments [10].
Nebulizers
Nebulizers convert liquid medication into a fine mist that can be inhaled over several minutes, making them particularly suitable for patients unable to use handheld inhalers effectively. These devices are commonly used in hospital settings, for pediatric patients, or in individuals with severe respiratory distress who cannot coordinate inhalation with device actuation [11].
There are several types of nebulizers, including jet (pneumatic) nebulizers, which use compressed air to generate aerosol; ultrasonic nebulizers, which employ high-frequency vibrations; and mesh (vibrating membrane) nebulizers, which force liquid through a fine mesh to produce droplets [12]. Mesh nebulizers are generally more efficient, quieter, and portable compared to traditional jet models.
Nebulizers do not require active patient participation in aerosol generation, eliminating the need for inspiratory effort or coordination. However, they are less portable than pMDIs and DPIs, require longer administration times (typically 5–15 minutes), and necessitate regular cleaning and maintenance to prevent microbial contamination [13]. They are often used for delivering bronchodilators like during acute exacerbations or for administering specialized therapies such as inhaled antibiotics in patients with .
Comparative Performance and Selection Criteria
The choice of inhaler type depends on multiple factors, including patient age, cognitive and physical abilities, inspiratory flow rate, and disease severity. A comparative analysis reveals key differences:
| Feature | pMDI | DPI | Nebulizer |
|---|---|---|---|
| Propellant Required | Yes (HFA) | No | No (uses air or ultrasound) |
| Hand-Breath Coordination | Required | Not required | Not required |
| Inspiratory Flow Needed | Low (improved with spacer) | High (>60 L/min) | None |
| Administration Time | <1 minute | <1 minute | 5–15 minutes |
| Portability | High | High | Low to moderate |
| Environmental Impact | Higher (due to HFA GWP) | Lower | Variable |
The selection process should be individualized, with healthcare professionals assessing patient capabilities and preferences. For instance, infants and young children often benefit from pMDIs with spacers and masks, while autonomous adults with good inspiratory flow may prefer DPIs for convenience and environmental sustainability. Patients with severe airflow limitation or cognitive impairments may require nebulizers for reliable drug delivery [16].
Ultimately, the effectiveness of any inhaler is contingent upon correct technique and patient education. Regular assessment and reinforcement of inhalation skills by , , or respiratory therapists are essential to ensure optimal therapeutic outcomes and minimize the risk of treatment failure or hospitalization [17].
Medical Uses in Respiratory Diseases
Inhalers are a cornerstone in the management of chronic respiratory diseases, providing targeted delivery of medication directly to the lungs. This method ensures rapid therapeutic effects while minimizing systemic side effects. The primary conditions treated with inhalers are and , both of which involve airway obstruction and inflammation. By administering drugs such as and directly into the respiratory tract, inhalers help control symptoms, prevent exacerbations, and improve patients' quality of life [1].
Asthma Management
Asthma is a chronic inflammatory condition of the airways characterized by episodes of wheezing, shortness of breath, chest tightness, and coughing. Inhalers play a dual role in asthma treatment: long-term control and acute symptom relief. For maintenance therapy, (ICS) such as are used to reduce airway inflammation and prevent exacerbations [19]. These medications are typically taken daily, even when symptoms are absent, to maintain airway stability.
For rapid relief during asthma attacks, short-acting beta-2 agonists (SABA) like are administered via inhalers. These act quickly—often within minutes—to relax the smooth muscles of the airways, alleviating bronchospasm and improving airflow [20]. In more severe or persistent cases, combination therapy may be prescribed, integrating ICS with long-acting beta-2 agonists (LABA) to enhance disease control. Devices such as or are commonly used, with the choice depending on patient age, coordination ability, and inspiratory strength [21].
Chronic Obstructive Pulmonary Disease (COPD) Treatment
COPD is a progressive lung disease that includes chronic bronchitis and emphysema, leading to airflow limitation and breathing difficulties. Like asthma, it is managed using inhalers, but the treatment strategy focuses more on symptom control, reduction of exacerbation frequency, and slowing disease progression. The main classes of inhaled medications used in COPD include long-acting bronchodilators—such as long-acting muscarinic antagonists (LAMA) and LABA—which help relax airway muscles and improve lung function [22].
For patients with frequent exacerbations, inhaled corticosteroids may be added to bronchodilator therapy, particularly in combination with LABA. Triple therapy, which combines ICS, LABA, and LAMA in a single inhaler (e.g., Breztri™), has been shown to improve outcomes in moderate to severe COPD [23]. The selection of inhaler type—whether , , or —depends on the patient's ability to generate sufficient inspiratory flow, especially since DPIs require a high inspiratory effort to disperse the powdered medication effectively [24].
Use in Other Respiratory Conditions
Beyond asthma and COPD, inhalers are also used in the management of other respiratory conditions. For example, chronic bronchitis, often a component of COPD, benefits from bronchodilator therapy to ease mucus clearance and reduce airway resistance. In certain cases, such as cystic fibrosis or bronchiectasis, inhaled antibiotics like tobramycin may be delivered via to treat recurrent lung infections [13]. Additionally, inhaled anticholinergics and beta-agonists are sometimes used in the treatment of bronchiolitis obliterans or post-transplant lung complications.
Importance of Correct Device Selection and Technique
The effectiveness of inhaler therapy is highly dependent on proper device selection and patient technique. Different inhaler types have distinct requirements: demands precise coordination between actuation and inhalation, while relies on a strong and rapid inhalation to release the medication [17]. For patients who struggle with coordination—such as young children or the elderly—using a with a pMDI can significantly improve drug delivery to the lungs [5].
Moreover, incorrect use of inhalers is alarmingly common, with studies indicating that up to 94% of patients make critical errors, leading to poor disease control and increased risk of hospitalization [28]. Therefore, healthcare professionals such as , , and respiratory therapists play a vital role in educating patients on correct inhalation techniques and regularly assessing their performance [17].
Monitoring and Adjusting Therapy
Clinical assessment of symptom control is essential in managing respiratory diseases. Tools such as the and the modified help quantify disease severity and guide treatment adjustments [30]. Objective measures like —which evaluates forced expiratory volume in one second (FEV1) and forced vital capacity (FVC)—are used to monitor lung function and assess response to therapy [31].
Treatment regimens are adjusted based on symptom frequency, exacerbation history, and lung function trends. In asthma, a stepwise approach is followed, escalating therapy if control is inadequate or de-escalating when symptoms are well-managed. In COPD, treatment intensity is guided by symptom burden and exacerbation risk, often categorized using the GOLD (Global Initiative for Chronic Obstructive Lung Disease) classification system [32].
In summary, inhalers are indispensable in the treatment of respiratory diseases, offering a targeted, effective, and generally well-tolerated method of drug delivery. Their success, however, hinges on appropriate device selection, correct technique, and ongoing patient education and monitoring by healthcare providers.
Proper Inhalation Technique and Common Errors
Proper inhalation technique is critical for ensuring that medication reaches the lungs effectively, maximizing therapeutic benefits and minimizing systemic side effects. Incorrect use of an can significantly reduce drug delivery to the airways, leading to poor symptom control, increased exacerbations, and higher risks of hospitalization [1]. Studies suggest that up to 94% of patients make at least one error when using their inhaler, underscoring the importance of education and regular technique checks by healthcare professionals [28].
Step-by-Step Guide to Correct Inhalation Technique
The proper use of an inhaler varies depending on the device type—such as or —but several general principles apply across all devices.
-
Preparation of the Device
Before use, patients should ensure the inhaler contains medication. For pMDIs, shaking the device is essential to mix the medication and propellant properly [35]. If the inhaler is new or has not been used for more than 14 days, it should be primed by releasing one or more test sprays into the air, according to manufacturer instructions [36]. -
Adopting the Correct Posture
The patient should sit or stand upright to allow for full lung expansion and deep breathing [17]. -
Exhalation Before Inhalation
The patient should exhale fully to empty the lungs, but not into the inhaler, especially with DPIs, as moisture can cause clumping of the powder [38]. -
Inhalation Process
- For pMDIs: Place the mouthpiece between the lips, seal tightly, and begin inhaling slowly and deeply. Press the canister to release the medication at the start of inhalation to ensure synchronization [35].
- For DPIs (e.g., Turbuhaler, Breezhaler): Inhale rapidly and deeply through the mouth. No manual activation is needed; the airflow triggers the release of the powdered medication [40].
-
Breath Holding
After inhalation, the patient should hold their breath for approximately 10 seconds to allow the medication to deposit in the lower airways [17]. -
Exhalation and Post-Use Care
Exhale slowly away from the device. If the inhaler contains an , the patient should rinse the mouth with water to prevent oral thrush and dysphonia [42]. -
Cleaning and Maintenance
The mouthpiece should be wiped with a dry cloth at least weekly. Avoid washing pMDIs with water, as this can damage internal components [35].
Use of Spacers and Valved Holding Chambers
For patients using pMDIs, especially children, elderly individuals, or those with coordination difficulties, a or valved holding chamber is highly recommended. These devices eliminate the need for precise hand-breath coordination by allowing the medication to be released into a chamber first, then inhaled slowly and deeply [44]. Spacers reduce oropharyngeal deposition of medication, thereby decreasing local side effects such as candidiasis and improving lung delivery [45]. They are particularly beneficial for patients on long-term and are considered standard of care in pediatric asthma management [46].
Common Errors in Inhaler Use
Despite clear instructions, many patients commit critical errors that compromise treatment efficacy. The most frequent mistakes include:
- Failure to exhale before inhalation, reducing the volume available for medication penetration [17].
- Poor coordination between actuation and inhalation in pMDIs, resulting in medication being sprayed into the mouth rather than the lungs [48].
- Insufficient or overly rapid inhalation, particularly with DPIs, which require a strong, fast breath to disperse the powder effectively [16].
- Not holding the breath after inhalation, limiting drug deposition in the alveoli [48].
- Exhaling into the inhaler, especially with DPIs, which can cause moisture buildup and clogging [17].
- Using an empty or unprimed inhaler, leading to missed doses [17].
- Inadequate cleaning, promoting microbial growth and device obstruction [1].
These errors are associated with a doubling of hospitalization risk and increased exacerbation frequency, particularly in patients with [54].
Strategies to Improve Technique and Adherence
To address these issues, a structured approach involving education, demonstration, and follow-up is essential. The “teach-back” method—where the patient demonstrates their technique immediately after instruction—has been shown to significantly improve mastery [55]. Regular verification of technique by a , , or nurse during follow-up visits is crucial, as patients often believe they are using their inhaler correctly when they are not [56].
Personalized device selection based on patient characteristics—such as age, inspiratory flow rate, cognitive ability, and dexterity—is another key factor. For example, DPIs require a minimum inspiratory flow (>60 L/min), making them unsuitable for some elderly or severely ill patients [8]. In such cases, pMDIs with spacers or may be more appropriate.
Digital tools such as with integrated are emerging as effective aids for monitoring adherence and technique in real time. These devices provide feedback via mobile applications, helping patients correct errors and maintain consistent use [58]. However, accessibility and cost remain barriers to widespread adoption.
Ultimately, optimal inhaler use depends on a collaborative effort among patients, , and caregivers, supported by ongoing education and the use of appropriate devices tailored to individual needs [17].
Role of Healthcare Professionals in Patient Education
Healthcare professionals play a pivotal role in ensuring the effective use of inhalation therapy for chronic respiratory diseases such as and . Given that up to 94% of patients use their inhalers incorrectly, leading to poor disease control and a doubled risk of hospitalization, the educational role of clinicians is not merely supportive but essential to therapeutic success [54]. The responsibility spans multiple disciplines, including , , , and , each contributing uniquely to patient understanding and adherence.
Assessment and Demonstration of Inhalation Technique
A cornerstone of patient education is the direct assessment and correction of inhalation technique. Clinicians must verify a patient’s ability to use their prescribed device through real-time demonstration during consultations. This process involves identifying common errors such as insufficient exhalation before inhalation, poor coordination between actuation and inhalation (particularly with , failure to inhale slowly and deeply, or not holding the breath for 5–10 seconds post-inhalation [56]. Standardized checklists specific to each inhaler type are recommended to ensure objective and reproducible evaluation [62]. The “teach-back” method—where patients demonstrate the technique immediately after instruction—is a proven strategy for reinforcing learning and correcting mistakes in real time [55].
Personalized Device Selection and Patient-Centered Care
The choice of inhalation device must be individualized based on the patient’s physical, cognitive, and psychosocial profile. For instance, patients with low inspiratory flow, such as those with severe or the elderly, may struggle with , which require a high inspiratory effort (>60 L/min) to disperse the medication effectively [8]. In contrast, with a valved holding chamber (spacer) are often more suitable, as they do not depend on inspiratory force and mitigate coordination challenges [5]. For young children, spacers with masks are the preferred option, while adolescents and adults may benefit from devices aligned with their preferences to enhance adherence [66]. The patient’s dexterity, cognitive ability, and personal preference significantly influence long-term compliance, making shared decision-making a critical component of care [67].
Ongoing Education and Multidisciplinary Collaboration
Education is not a one-time event but an ongoing process requiring reinforcement at every clinical encounter. Regular re-evaluation of technique is necessary, as skills can deteriorate over time even in experienced users [68]. Pharmacists, in particular, are uniquely positioned to provide immediate, practical training at the point of medication dispensing, making them key players in inhaler education [17]. Collaborative models, such as structured inhaler interviews integrated into medication reviews, have demonstrated significant improvements in both technique and adherence [70]. Programs like “Les Jeux de l’Air” in France have also shown success in improving asthma management through interactive, game-based learning for children [71].
Use of Educational Tools and Digital Technologies
Healthcare professionals increasingly leverage educational aids to enhance learning. These include official guides from organizations like the , instructional videos, placebo inhalers for practice, and digital tools such as mobile applications and smart inhalers equipped with [1]. Smart inhalers provide real-time feedback on usage patterns and technique, enabling personalized coaching and early detection of deteriorating control [73]. Artificial intelligence platforms, such as the collaboration between CHIESI and HEPHAÏ, analyze inhaler use data to guide patients toward optimal technique [74].
Addressing Barriers to Adherence and Health Inequities
Professionals must also identify and address barriers to adherence, including cost, complexity of regimens, fear of side effects, and lack of perceived need. In low-income settings, financial constraints and medication shortages severely limit access to essential inhalers, exacerbating health disparities [75]. Educational interventions must be culturally sensitive and adapted to local contexts, particularly in regions with limited healthcare infrastructure. International initiatives like the and Access Oxygen work to improve access to affordable inhalation therapies in low- and middle-income countries [76]. In high-income countries, geographic disparities persist, with rural and underserved populations facing reduced access to specialized care and educational programs [77].
In summary, healthcare professionals are central to optimizing inhalation therapy through comprehensive, patient-centered education. By assessing technique, selecting appropriate devices, providing continuous training, and utilizing innovative tools, they ensure that patients receive the full therapeutic benefit of their medications. This multidisciplinary, iterative approach is fundamental to improving disease control, reducing exacerbations, and enhancing the quality of life for individuals with chronic respiratory conditions.
Technological Innovations and Smart Inhalers
Recent advancements in respiratory medicine have led to significant technological innovations in inhalation therapy, transforming the management of chronic conditions such as and . These innovations focus on enhancing treatment efficacy, improving patient adherence, and reducing environmental impact. Among the most impactful developments are smart inhalers equipped with digital tracking systems, advanced formulation technologies, and eco-friendly alternatives to traditional propellant-based devices.
Smart Inhalers and Digital Monitoring
One of the most transformative innovations in inhalation therapy is the development of smart inhalers, which integrate electronic sensors and digital connectivity to monitor and improve patient adherence and technique. These devices are equipped with sensors—such as accelerometers and flow detectors—that record critical data including the time, date, duration, and quality of each inhalation [78]. This data is transmitted via Bluetooth to mobile applications, enabling real-time feedback for patients and remote monitoring by healthcare providers [73].
Smart inhalers address a major challenge in respiratory care: poor adherence. Studies show that up to 90% of patients do not use their inhalers correctly, significantly reducing treatment efficacy [73]. By providing immediate feedback on inhalation technique—such as coordination between actuation and inspiration or insufficient breath-holding—these devices help correct errors and reinforce proper use. For example, the HeroTracker® Sense by Aptar and the Breezhaler® connected by Novartis incorporate sensors that guide patients toward optimal inhalation patterns [81], [82].
Moreover, smart inhalers support predictive healthcare. By analyzing patterns such as increased use of rescue inhalers, these systems can detect early signs of exacerbations in COPD or asthma, enabling timely interventions and reducing hospitalizations [83]. A Cochrane review confirmed that digital technologies significantly improve medication adherence and reduce exacerbations in asthma patients [84].
Advanced Formulations and Eco-Friendly Propellants
Technological progress extends beyond digital integration to include innovations in drug formulation and delivery mechanisms. Traditional pressurized metered-dose inhalers (pMDIs) have historically relied on chlorofluorocarbons (CFCs) as propellants, which were phased out due to their ozone-depleting effects. Modern pMDIs now use hydrofluoroalkanes (HFAs), such as HFA-134a, which are ozone-safe but still have a high global warming potential (GWP) [3]. To address this, new propellants with near-zero GWP, such as hydrofluoroolefins (HFOs), are being introduced, significantly reducing the carbon footprint of inhalation therapy [86].
Dry powder inhalers (DPIs) and soft-mist inhalers (SMIs) like the Respimat® offer inherently more sustainable alternatives, as they do not require propellant gases. DPIs, such as the Turbuhaler and Diskus, rely on the patient’s inspiratory effort to disperse the medication, eliminating the need for chemical propellants and reducing environmental impact [9]. These devices are not only eco-friendly but also highly effective, particularly for patients who struggle with coordination required by pMDIs.
Additionally, advanced formulations now allow for more efficient drug delivery. Techniques such as micronization and spray drying produce particles with an optimal aerodynamic diameter (1–5 μm), ensuring deep lung deposition and enhanced therapeutic effect [88]. Innovations like porous or hollow particles further improve lung retention and bioavailability [89].
Integration with Clinical Decision-Making
Smart inhalers and digital health platforms are increasingly integrated into clinical workflows, supporting personalized and data-driven care. The data collected from these devices can be shared with , , and primary care providers, enabling more informed decisions during consultations. For instance, the STRATEGY SMART approach, which combines maintenance and reliever therapy in a single inhaler, benefits from digital monitoring to validate adherence and adjust dosing in real time [90].
Furthermore, artificial intelligence (AI) is being applied to analyze inhaler usage patterns. Collaborations such as the one between CHIESI and HEPHAÏ have developed AI-powered systems that provide personalized guidance to patients, improving inhalation technique and long-term outcomes [74].
Challenges and Future Directions
Despite their promise, smart inhalers face challenges related to cost, data privacy, interoperability with healthcare systems, and patient acceptance, particularly among elderly populations [92]. Additionally, while improved adherence has been demonstrated, direct clinical benefits such as reduced exacerbations are still being evaluated in real-world settings.
Nevertheless, the trajectory of innovation points toward a future of connected, personalized, and sustainable respiratory care. As digital health ecosystems mature and regulatory frameworks evolve—such as the EU’s Medical Device Regulation (MDR) and ISO standards for biocompatibility [93]—smart inhalers are poised to become a cornerstone of modern respiratory management, enhancing both patient outcomes and environmental stewardship.
Environmental Impact and Sustainable Alternatives
The widespread use of has raised significant concerns regarding their environmental footprint, particularly due to the propellants they employ. Historically, these devices used , which were found to severely deplete the , prompting international action under the of 1987 [94]. This landmark agreement led to the global phase-out of CFCs in medical and industrial applications, marking a critical step in environmental protection [95].
Transition to HFA Propellants and Ongoing Climate Concerns
In response to the CFC ban, pharmaceutical manufacturers transitioned to , such as HFA-134a and HFA-227, which do not harm the ozone layer. While this resolved the ozone depletion issue, HFAs are potent greenhouse gases with a high . For instance, HFA-134a has a GWP of approximately 1,430, meaning it traps 1,430 times more heat in the atmosphere than an equivalent mass of carbon dioxide over a 100-year period [96]. The environmental cost of a single pMDI can equate to 10 to 40 kilograms of CO₂ emissions, and on a national scale, inhaler use can contribute over 900,000 tonnes of CO₂ equivalent annually [97]. This significant carbon footprint has become a focal point for healthcare systems aiming for sustainability.
Sustainable Alternatives: Dry Powder Inhalers and Low-GWP Propellants
To mitigate this environmental impact, several sustainable alternatives have been developed and promoted. The most prominent alternative is the , which requires no propellant gas. Instead, it relies on the patient's own inspiratory effort to aerosolize the medication, resulting in a dramatically lower carbon footprint compared to pMDIs [9]. The adoption of DPIs is a key strategy in reducing the environmental burden of respiratory therapy, especially for patients whose pulmonary function allows for the necessary inspiratory flow rate.
Furthermore, the industry is innovating with new propellants that have a near-zero GWP. One such example is HFA-152a, which has a GWP of around 124, a substantial reduction from HFA-134a. These low-GWP propellants offer a viable path for patients who cannot use DPIs, allowing for a more sustainable pMDI option without compromising on the need for a pressurized delivery system [99]. Companies like and are investing in the development and production of inhalers with these next-generation propellants, with AstraZeneca reporting a 96% reduction in CO₂ emissions at one of its manufacturing sites [100].
Role of Public Health Policies and Clinical Practice
Public health policies play a crucial role in accelerating the shift toward sustainable inhalation therapy. Initiatives such as PhareClimat in France have demonstrated success in reducing the prescription of high-GWP pMDIs by 51% in primary care between 2022 and 2025, replacing them with more eco-friendly alternatives [101]. Clinical guidelines are increasingly incorporating environmental considerations, encouraging physicians to choose the most effective device with the lowest environmental impact, a practice known as "green prescribing" [102]. This is supported by international agreements like the to the Montreal Protocol, which mandates a global phasedown of hydrofluorocarbons (HFCs), the class of gases that includes HFAs [103].
Synergy of Environmental and Clinical Benefits
Importantly, the move toward sustainable inhalers does not come at the cost of therapeutic efficacy. Studies, including those from , suggest that switching to eco-friendly devices, such as DPIs for patients, can lead to improved clinical outcomes, including better symptom control and fewer exacerbations [104]. This convergence of environmental and health benefits strengthens the case for sustainable alternatives. The integration of these devices into clinical practice, supported by robust on proper inhalation technique, ensures that the transition enhances both planetary and patient health. The future of inhaler therapy lies in a balanced approach that prioritizes the efficacy of treatment, the empowerment of the patient, and the sustainability of the healthcare system.
Device Selection Based on Patient Factors
Selecting the appropriate inhaler device is a critical step in the management of chronic respiratory diseases such as and . The choice must be individualized, taking into account various patient-specific factors to ensure optimal drug delivery, therapeutic efficacy, and adherence to treatment. A mismatch between the patient’s capabilities and the device requirements can lead to improper use, reduced lung deposition of medication, poor symptom control, and increased risk of exacerbations and hospitalizations [54].
Age and Developmental Stage
Age is a primary determinant in inhaler selection, as it influences both physical ability and cognitive understanding. For children under 3 years, the preferred option is a used in conjunction with a valved holding chamber and a facial mask, as this combination does not require coordination or strong inspiratory effort [66]. Between the ages of 3 and 5, the use of a mouthpiece with a chamber is often introduced if the child can cooperate. For children aged 6 years and older, both pMDIs and become viable options, provided the child has adequate inspiratory capacity and can follow instructions [107].
In adolescents and adults, the choice expands to include a wider range of devices, including pMDIs, DPIs, and soft-mist inhalers like . However, even within this group, individual capabilities must be assessed. For older adults, age-related declines in manual dexterity, cognitive function, and inspiratory strength may limit the use of certain devices. DPIs, which require a high inspiratory flow rate (often >60 L/min), may be less suitable for elderly patients with compromised lung function, making pMDIs with a spacer a more reliable alternative [5].
Inspiratory Flow Rate and Respiratory Capacity
The patient’s inspiratory flow rate is a crucial physiological factor, particularly when considering DPIs. These devices rely entirely on the patient’s inhalation to disperse and deliver the powdered medication. If the inspiratory flow is insufficient, the powder will not be adequately aerosolized, leading to suboptimal dosing [8]. Devices such as the can be used in clinical settings to measure a patient’s peak inspiratory flow, helping clinicians determine whether a DPI is appropriate [110].
In contrast, pMDIs do not depend on inspiratory flow for drug release, although coordination between actuation and inhalation is required. This coordination challenge can be overcome by using a spacer, which decouples the actuation from the inhalation phase, allowing the patient to inhale slowly and deeply from the chamber after the medication has been released [5]. This makes pMDIs with spacers particularly beneficial for patients with weak inspiratory effort or poor coordination.
Cognitive and Physical Abilities
Cognitive function and manual dexterity significantly influence a patient’s ability to use inhalers correctly. Patients with cognitive impairments, such as those with dementia or neurological conditions, may struggle with multi-step procedures required by some DPIs or pMDIs. In such cases, simpler devices or those with built-in dose counters (e.g., ) can improve adherence and reduce errors [6].
Physical limitations, such as arthritis or tremors, can also hinder the use of devices requiring precise hand movements. Auto-inhalers or breath-actuated pMDIs can be advantageous in these situations, as they eliminate the need for manual coordination. Additionally, the number of steps involved in preparing and using the device should be minimized to reduce the cognitive load on the patient.
Coordination and Technique Requirements
The need for hand-breath coordination is a major differentiator between inhaler types. pMDIs require precise timing between pressing the canister and inhaling, a skill that many patients, especially children and the elderly, find difficult to master. Studies show that up to 94% of patients make at least one critical error when using their inhaler, often related to poor coordination [113].
DPIs do not require this coordination, as the inhalation itself triggers the release of medication. However, they demand a rapid and forceful inhalation, which can be challenging for some patients. Soft-mist inhalers like offer a compromise, generating a slow-moving aerosol that is easier to inhale and less dependent on perfect technique, making them suitable for patients with coordination difficulties [114].
Patient Preferences and Lifestyle
Patient preference plays a significant role in long-term adherence. Devices that are perceived as complex, inconvenient, or stigmatizing are more likely to be used incorrectly or abandoned altogether. Factors such as portability, ease of cleaning, and the number of daily doses influence patient satisfaction. For instance, DPIs are often favored for their compact size and lack of propellant, making them more environmentally friendly and easier to carry [9].
Engaging patients in the decision-making process and considering their lifestyle and preferences can enhance treatment acceptance. For example, a patient who travels frequently may prefer a lightweight, durable device, while someone with visual impairments may benefit from an inhaler with tactile or auditory feedback.
Clinical Context and Disease Severity
The clinical context, including disease severity and stability, also guides device selection. In acute settings or during exacerbations, when patients may be too breathless to generate sufficient inspiratory flow, nebulizers are often preferred. These devices deliver medication as a fine mist over several minutes, requiring minimal patient effort and no coordination [1].
For stable, long-term management, handheld devices are typically more practical. In patients with frequent exacerbations or poor control, combination therapies (e.g., with long-acting bronchodilators) may be necessary, and the availability of such combinations in a single inhaler (e.g., , ) can simplify treatment regimens and improve adherence [23].
Environmental and Economic Considerations
While not directly related to patient physiology, environmental impact and cost are increasingly relevant in device selection. pMDIs using hydrofluoroalkane (HFA) propellants have a high global warming potential, prompting public health initiatives to promote the use of more sustainable alternatives like DPIs [118]. Programs such as PhareClimat in France have successfully reduced HFA prescriptions by promoting eco-friendly options without compromising clinical outcomes [101].
Cost and insurance coverage also affect access, particularly in low- and middle-income countries where even generic inhalers may be unaffordable. In these settings, the availability of low-cost DPIs or access programs supported by organizations like the can be critical for ensuring equitable treatment [76].
In summary, the selection of an inhaler must be a personalized process that considers the patient’s age, inspiratory capacity, cognitive and physical abilities, lifestyle, and clinical needs. Regular assessment of inhalation technique by healthcare professionals such as , , and is essential to ensure ongoing efficacy and to make adjustments as the patient’s condition or capabilities change [17].
Regulatory Standards and In Vitro Testing
The development, performance, and safety of inhalation devices are governed by a comprehensive framework of international regulatory standards and rigorous in vitro testing protocols. These standards ensure that inhalers deliver medication effectively, consistently, and safely to the lungs, while also addressing the biocompatibility of materials that come into contact with the respiratory system. The adherence to these guidelines is mandatory for market approval and is overseen by regulatory bodies such as the and [122].
Performance Testing and Aerosol Characterization
The in vitro performance of inhalers is evaluated using a suite of standardized methodologies designed to simulate real-world use and measure critical aerosol properties. A primary focus is on the characterization of the aerosol generated by the device, which directly influences the drug's ability to reach the lower airways. Key parameters include the Mass Median Aerodynamic Diameter (MMAD), which defines the size of particles that will deposit in specific regions of the respiratory tract. Particles with an MMAD between 1 and 5 micrometers are considered optimal for deep lung deposition, as larger particles (>5 µm) tend to deposit in the oropharyngeal region, while smaller ones (<1 µm) are often exhaled [8][124].
The distribution of particle size is measured using sophisticated instruments such as cascade impactors, which separate particles by size based on their inertia. Devices like the Next Generation Impactor (NGI) are used to determine the Fine Particle Fraction (FPF), the proportion of emitted dose with particles smaller than 5 µm, a critical metric for assessing a device's potential for effective pulmonary delivery [125]. Other techniques, including laser diffraction and dynamic light scattering, provide additional data on particle size distribution [126]. Advanced methods like Particle Image Velocimetry (PIV) and optical sensors are also employed to analyze the velocity and trajectory of aerosol particles, providing insights into the aerodynamic behavior of the spray [127].
Key International Standards for Device Performance
Several international standards, developed by the International Organization for Standardization (ISO), form the backbone of inhaler performance testing. The standard specifies the requirements and test methods for portable, hand-held, aerosol drug delivery devices, including pressurized metered-dose inhalers (pMDI). It covers aspects such as design verification, functionality, delivered dose uniformity, and user instructions [128]. For nebulizer systems, outlines the safety and performance test methods, focusing on droplet size, nebulization rate, and drug stability [129]. These tests are conducted under controlled conditions that simulate various inhalation profiles, allowing for an objective comparison of different devices and formulations. The data generated from these in vitro tests are essential for demonstrating bioequivalence between generic and brand-name products and for ensuring batch-to-batch consistency.
Biocompatibility and Material Safety Testing
Beyond performance, the safety of the materials used in inhaler construction is paramount. The ISO 18562 series is the primary international standard for evaluating the biocompatibility of respiratory gas pathways in medical devices. This standard is crucial because components of the inhaler can release particulates or volatile substances that are inhaled directly into the lungs. specifically addresses the emissions of fine and ultrafine particulate matter, which can cause inflammation or other adverse effects due to their deep penetration potential [130]. deals with the emissions of volatile organic compounds (VOCs), which may cause irritation or systemic toxicity [131]. These standards are based on a risk management process and require manufacturers to conduct thorough testing to ensure patient safety.
The evaluation of material toxicity often involves advanced in vitro models, such as air-liquid interface (ALI) cell cultures, which provide a more accurate prediction of pulmonary toxicity by exposing lung epithelial cells to aerosols under conditions that mimic the alveolar environment [132]. These models are increasingly seen as a more relevant alternative to animal testing. Regulatory agencies like the mandate strict compliance with these biocompatibility standards to guarantee the long-term safety of patients with chronic respiratory conditions like and [133].
Modeling and Simulation for Predictive Assessment
To further enhance the evaluation process, in vitro models are used to simulate pulmonary deposition. These systems typically consist of an anatomical model of the mouth and throat, a programmable breathing simulator, and a collection system such as an impactor. By controlling the inhalation profile, these models can predict how factors like inhalation technique or patient age might affect drug delivery [134]. These simulations are often complemented by in silico modeling, which uses computational fluid dynamics and anatomical data to create personalized predictions of drug deposition based on a patient's specific physiology [135]. This integrated approach of in vitro testing, standardized by ISO protocols and supported by advanced modeling, ensures that inhalers are not only effective but also safe and reliable for all users.
Global Access and Health Equity Challenges
Access to therapy remains profoundly unequal across the globe, creating significant health disparities for individuals with chronic respiratory diseases such as and . While these devices are essential for managing symptoms and preventing life-threatening exacerbations, their availability, affordability, and effective use are heavily influenced by geographic location, socioeconomic status, and national health infrastructure. This section explores the multifaceted challenges to equitable access and the strategies being implemented to address them.
Disparities in Availability and Geographic Access
The availability of inhalers varies dramatically between high-income and low- to middle-income countries (LMICs). In high-income nations, inhalation therapy is generally well-integrated into healthcare systems, although even there, periodic shortages of essential medications like (e.g., Ventolin) can occur due to disruptions in the global supply chain [136]. In contrast, LMICs face chronic and severe shortages. For example, in countries like Ecuador, deteriorating access to inhaled medications has been linked to increased premature deaths and a significant decline in patients' quality of life [137]. The situation is particularly dire in rural areas and so-called "medical deserts," both in developed and developing nations, where a lack of healthcare professionals and poor infrastructure severely limits access to essential respiratory care [138].
Financial Barriers and Affordability
Cost is a primary barrier to access in LMICs and for low-income populations in wealthier countries. The median cost of inhalers for asthma and COPD can be prohibitively high relative to average incomes. In Morocco, for instance, an inhaler can cost up to 130 DH (approximately 13 USD), representing a substantial portion of a low-income household's monthly budget [139]. Even in Europe, direct out-of-pocket payments for primary care, including inhaled medications, have become unaffordable for millions [140]. These financial barriers force many patients to ration their medication or forgo treatment entirely, leading to poorly controlled disease and increased hospitalization rates.
Socioeconomic and Educational Determinants
Access to effective inhaler therapy is also shaped by socioeconomic and educational factors. Populations with lower education levels or from marginalized racial and ethnic groups often experience higher rates of asthma and COPD morbidity and mortality. This is frequently linked to social determinants of health, such as substandard housing, higher exposure to air pollution, and limited health literacy [141]. A lack of understanding about the disease and its management can lead to poor adherence to treatment and incorrect use of inhalers. The pandemic of COVID-19 further widened these socioeconomic disparities, disrupting preventive care and exacerbating existing structural inequalities in healthcare access [142].
Challenges in Proper Use and Education
Even when inhalers are available, their effectiveness is compromised by widespread errors in use. Studies show that up to 94% of patients use their inhalers incorrectly, which drastically reduces the amount of medication reaching the lungs and is associated with a doubled risk of hospitalization [54]. This problem is amplified in resource-limited settings where access to structured programs is scarce. Effective use of different inhaler types—such as the need for coordination with or sufficient inspiratory flow for —requires patient training and regular follow-up by healthcare professionals like and . The lack of such support in underserved areas is a critical gap in care.
Strategies to Improve Equity
Efforts to reduce these inequities are multifaceted. The advocates for the inclusion of essential inhaled medications in national essential medicines lists to improve availability [75]. International initiatives, such as the supported by the UN, work to increase access to generic inhalers by negotiating licenses with patent holders, enabling lower-cost production [76]. Programs like Access Oxygen are working to improve the availability and reliability of oxygen and inhalation devices in Africa [146]. Domestically, policies promoting the use of more sustainable and often more affordable alternatives, like DPIs, are being implemented. For example, initiatives like PhareClimat in France have successfully reduced the prescription of high-GWP HFA inhalers in primary care [101]. Crucially, integrating structured programs into care pathways has proven effective in improving inhaler technique, adherence, and disease control, and is a key recommendation from bodies like the [148]. These combined strategies—improving supply chains, reducing costs, and enhancing patient education—are essential for achieving health equity in respiratory care.